ArticleCancer immunology, immunotherapy : CII2021
Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors.
Article in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review.British journal of cancer · 2025Pooled it
- Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants.The pharmacogenomics journal · 2026Article
- Exposure-response relationship of sintilimab in advanced gastric cancer: insights from time-dependent pharmacokinetics and biomarker integration for precision immunotherapy.Frontiers in pharmacology · 2026Review
- Development of immune-related adverse events is associated with improved survival outcomes in cancer patients receiving immune checkpoint inhibitors.Frontiers in immunology · 2026Article
- rs10204525 binding to miR-4717-3p modulates PD-1 expression and predicts the development of immune-related adverse events in patients with advanced cancer treated with anti-PD-1/PD-L1 therapy.Journal for immunotherapy of cancer · 2025Article
- Genetic haplotypes inJournal for immunotherapy of cancer · 2025Article
- Tumour SNPs Associated with Immune-Related Hepatitis in Patients with Melanoma Receiving Immune Checkpoint Inhibitors.Biomedicines · 2025Article
- Current status of management of immune-related adverse events and practical needs for oncologist education.Cancer biology & medicine · 2025Review
- The role of tumor types in immune-related adverse events.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- An Extremely Rare Case of Immune Checkpoint Inhibitors-Related Hypoparathyroidism and a Critical Literature Review.JCEM case reports · 2025Article
- Late-onset recurrent immune checkpoint inhibitor-related pneumonitis after cessation of pembrolizumab: a case report.Immunotherapy · 2025Article
- Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.JAMA network open · 2025Observational
- Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective Observational Study by Using the Common Data Model.Diagnostics (Basel, Switzerland) · 2025Article
- Activin A receptor type 1C single nucleotide polymorphisms associated with esophageal squamous cell carcinoma risk in Chinese population.World journal of gastrointestinal oncology · 2025Article
- Immune-Related Adverse Events of Checkpoint Inhibitors and Human Leukocyte Antigen System: A Review.ImmunoTargets and therapy · 2025Review
- Advances in the mechanisms, imaging characteristics and management strategies for immune checkpoint inhibitor-related pneumonitis.Frontiers in immunology · 2025Review
- Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes.Frontiers in immunology · 2025Review
- Immune checkpoint inhibitor therapy‑related pneumonitis: How, when and why to diagnose and manage (Review).Experimental and therapeutic medicine · 2024Review
- Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors.Hepatology communications · 2024Article
- Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors.World journal of clinical oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundImmune checkpoint inhibitors (ICIs) can cause profound immune-related adverse events (irAEs). The host genetic background is likely to play a role in irAE susceptibility because the presentation of toxicity varies among patients and many do not develop irAEs despite continued ICI use. We sought to identify potential genetic markers conferring risk for irAEs.
methodsWe conducted a pilot exploratory study in 89 melanoma patients who received ICIs (44 with irAEs, and 45 without irAEs after at least 1 year from starting treatment). Genotyping was performed using the Infinium Multi-Ethnic Global-8 v1.0 Bead Chip. The genotype data were extracted using PLINK (v1.90b3.34) and processed for quality control. Population structure-based clustering was carried out using IBS matrix, pairwise population concordance test (p < 1 × 10
resultsA total of 30 variants or single-nucleotide polymorphisms with p < 1 × 10
conclusionSeveral genetic variants associated with irAEs were identified. Additional larger studies are needed to validate these findings and establish their potential functional relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.